Penn Researchers Study New Treatment Options for Brain Cancer Patients
A team of Penn researchers are exploring whether MRIs that measure the "temperature" of tumors could enhance treatment for glioblastoma, a deadly brain cancer.
EpiVario Awarded NIH Grant to Advance Research in Treatments for Cocaine Use Disorder
EpiVario is developing neuroepigenetic modulators to treat memory-related addiction and psychiatric disorders.
Ultragenyx Announces FDA Acceptance and Priority Review of the Biologics License Application (BLA) for Sanfilippo Gene Therapy Based on Penn Technology
The drug relies on licensed foundational gene therapy technology created in the laboratory of Dr. James Wilson, MD, PhD.
Interius BioTherapeutics Receives Clearance to Begin Phase 1 Clinical Trial for Its First-in-Class In Vivo CAR Therapeutic for B Cell Malignancies
Interius intends to begin patient enrollment for the trial in the fourth quarter of 2024.
Development of RNA Therapeutics Targets Neurological Diseases
The collaboration combines Ascidian's RNA exon editing technology with Roche's expertise in CNS delivery to create novel treatments for hard-to-treat neurological conditions.
Cabaletta’s Early Data Shows Potential for Treating Autoimmune Diseases
The company reported positive results in the first two patients who received its new CAR T therapy, CABA-201, which aims to treat the autoimmune diseases lupus and myositis.
Heirloom Builds Direct Carbon Capture Facility
Heirloom has announced the first phase of a decarbonization project to create two Direct Air Capture (DAC) facilities in North Western Louisiana,
Development of RNA Therapeutics Targets Neurological Diseases
The collaboration combines Ascidian's RNA exon editing technology with Roche's expertise in CNS delivery to create novel treatments for hard-to-treat neurological conditions.
PCI and PACT Host AI Event for Philly Tech Week
PCI and the Philadelphia Alliance for Capital and Technologies (PACT) jointly presented a recent event called “AI Nexus: Shaping Tomorrow’s Intelligence."
A Rare Patient Mutation May Help Lead to More Effective Treatments for Genetic Bone Disease
Davis' relatively benign symptomology is attributed to low levels of the inflammatory protein MMP-9, which seems to prevent the characteristic abnormal bone formation.